Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HighTide TherapeuticsHTTIF 14 Cash-to-Debt is 3.96 as of Dec. 2025, which is 91% below its 10-year median of 44.77. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,402 Biotechnology companies, HighTide Therapeutics ranks worse than 57.63% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HighTide Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 3.96.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, HighTide Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for HighTide Therapeutics's Cash-to-Debt or its related term are showing as below:
HTTIF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.96 Med: 44.77 Max: 93.87
Current: 3.96
During the past 5 years, HighTide Therapeutics's highest Cash to Debt Ratio was 93.87. The lowest was 3.96. And the median was 44.77.
HTTIF's Cash-to-Debt is ranked worse than 57.63% of 1402
companies
in the Biotechnology industry
Industry Median: 6.52
vs HTTIF: 3.96
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
HighTide Therapeutics Cash-to-Debt Related Terms
HighTide Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for HighTide Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HTTIF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, HighTide Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HighTide Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where HighTide Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HighTide Therapeutics (HTTIF) has a Cash-to-Debt of 3.96 as of Dec. 2025. This is 91% below median its historical median of 44.77. Over the past decade, HighTide Therapeutics' Cash-to-Debt has ranged from 3.96 to 93.87. According to the industry distribution chart, HighTide Therapeutics ranks #808 out of 1402 companies in the Biotechnology industry, placing it in the top 57.6%.
Is HighTide Therapeutics' Cash-to-Debt too high?
HighTide Therapeutics' current Cash-to-Debt of 3.96 is 91% below median its 10-year median of 44.77. Over the past 10 years, this metric has ranged from a low of 3.96 to a high of 93.87. The Biotechnology industry median Cash-to-Debt is 6.52. HighTide Therapeutics' value of 3.96 is 39.3% below this industry median. Based on the distribution chart, HighTide Therapeutics ranks #808 out of 1402 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #808 out of 1402 companies for Cash-to-Debt. This places HighTide Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.52. HighTide Therapeutics' value of 3.96 is 39.3% below this benchmark. Historically, HighTide Therapeutics' own Cash-to-Debt has ranged from 3.96 to 93.87 over the past decade. While the company's 10-year median is 44.77 vs. the industry median of 6.52, HighTide Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.52, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HighTide Therapeutics's current Cash-to-Debt of 3.96 is 39.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HighTide Therapeutics's current Cash-to-Debt is 3.96, which is 91% below median its own 10-year median of 44.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Cash-to-Debt of 3.96. The current Cash-to-Debt is 3.96, which is 91% below median its 10-year median of 44.77 and 39.3% below the Biotechnology industry median of 6.52. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Cash-to-Debt is 3.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score
Get the complete analysis for HTTIF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTTIF has been successfully added to your 
